Carnot Curie Cancer
Curie Cancer is built on the expertise of Institut Curie (3200 people), a leading comprehensive cancer center in Europe and a world-renowned hospital.
Curie Cancer offers to industrial partners the ability to setup research collaborations from early discovery (cognitive research) to the most advanced research stages (clinical research).
Competences
Core business
Health
Technologies for health
Hight competences
Chemistry
Key figures
Fermer
Key figures
| Permanent staff (full-time equivalent) | 891 |
| including PhD Students | 179 |
| Global budget | 104,9 M€ |
| Partnership incomes with industry | 12,7 M€ |
Contact
Fermer
Contact
Institut Curie
Technology Transfer & Industrial Partnerships
26 rue d'Ulm
75248 Paris cedex 5
France
Amaury Martin
+33 (0)1 56 24 55 80
Géraldine Gubitta-Wane
+33 (0)1 56 24 55 84
Parent institutions
Presentation
From therapeutic target… to clinical validation
© Noak / Le Bar Floréal / Institut Curie
The model of Marie Curie
- Marie Curie, founder of Institut Curie, was attached to the seamless continuity from fundamental and clinical research to patient care. Curie Cancer maintains these dynamics and puts together leading teams in cognitive, translational and clinical research.
- Curie Cancer offers tailor-made collaborative research projects to industrial partners, based on the internal expertise of its teams as well as the capabilities of its advanced technical platforms.
- Curie Cancer is led by professionals with extensive experience in the pharmaceutical industry and/or biotechnology sector and thus sets up efficient collaborations with its industrial partners.
Examples of collaborative projects with industrial partners
- Identification and validation of therapeutic targets.
- Evaluation of drug efficiency and antitumor activity on human xenograft mice.
- Identification of biomarkers.
- Identification of the mechanism of drug activity in developmental medicinal chemistry.
- Design of monoclonal antibodies against therapeutic targets.
- Pharmacokinetic clinical studies in phase I, II or III in several types of cancer.
Target markets
- Health
- Cosmetics
Expertise and know-how
|
|
© Noak / Le Bar Floréal / Institut Curie / © Arnaud Echard / CNRS / Institut Curie
Technological platforms
- Bank of tumor tissus
- Xenografts in nude mice
- Transgenic mice, zebra-fish, …
- High-throughput sequencing
- High-throughput phenotypic screening
- Cyclotron to produce radioisotope with ultra-short half-life
- Imaging, bioinformatics, omics
